Innovative therapy option for OAB
  First And Only FDA-Approved Gel For The
Treatment Of Overactive Bladder (OAB) Symptoms

Thirty-four million men and women suffer from OAB syndrome.1 Every day, these patients live with symptoms, which may include urinary incontinence and urgency and frequency of urination. Treatment for OAB generally involves a combination of modalities including antimuscarinic medication and
behavioral therapy.2 Antimuscarinic agents are effective in most patients. Dry mouth and constipation are the most commonly reported adverse events, but orally administered agents are fairly well tolerated overall.1

“Oral medications are often effective, however the side effects may be too problematic for some patients,” said Scott MacDiarmid, MD, FRCPSC, director of Alliance Urology Specialists Bladder Control & Pelvic Pain Center. “Now a new alternative to oral medications is available in a gel form.”

Once-daily Gelnique (oxybutynin chloride) Gel 10% offers a unique combination of efficacy,1  tolerability1 and smart gel technology to modernize the treatment of OAB.

Gelnique is available for patients in pre-measured 1-gram unit doses (1.14 mL) of 100 mg/g oxybutynin chloride gel.3 Gelnique is applied once daily onto the abdomen, upper arm/shoulder, or thigh, before application of other lotions and creams.3 The gel is clear, fragrance-free, and leaves no residue.1 It also dries quickly, allowing patients to bathe, swim, or shower one hour after application.3
Gelnique is absorbed directly into the bloodstream through the skin and bypasses the gastric system and first-pass metabolism of the liver.3 Avoiding first-pass metabolism reduces the amount of N-desethyloxybutynin (N-DEO) metabolite in the bloodstream.3 Researchers believe N-DEO may play a role in the development of drying side effects, such as dry mouth, with oral oxybutynin.4,5 Gelnique offers proven safety for prescribing confidence.1 Additionally, treatment compliance with Gelnique was as high as 90.7% (91.2% for placebo) in the pivotal phase 3 clinical trial.1

“Gelnique appears to have lower incidence of constipation and dry mouth than oral medications,” said Dr. MacDiarmid, who also co-authored a study related to the gel treatment. “As with any medication, it’s important that each patient receives the proper evaluation to determine which treatment option is best for his or her situation.”

For more information about evaluation and treatment of OAB, contact Alliance Urology Specialists at 336-274-1114. To learn more about Gelnique and for full prescribing information, please visit

Important Safety Information
The most commonly reported adverse events associated with the use of Gelnique included dry mouth (6.9%), urinary tract infection (6.9%) and application site reactions (5.4%).  Gelnique is contraindicated in patients with urinary retention, gastric retention, uncontrolled narrow-angle glaucoma, or known hypersensitivity to Gelnique, including skin hypersensitivity and in patients who are at risk for these conditions.  Gelnique should be used with caution in patients with hepatic or renal impairment clinically significant bladder outflow obstruction, myasthenia gravis, and gastrointestinal obstructive disorders.  Gelnique should also be used with caution in patients with conditions such as ulcerative colitis, intestinal atony, gastroesophageal reflux and those concurrently taking drugs that can cause or exacerbate esophagitis.  Transference of oxybutynin to another person can occur when vigorous skin-to-skin contact is made with the application site.  Patients should be instructed to avoid open fire or smoking until the gel has dried.

Click here for prescribing information

  1. Staskin DR, Dmochowski RR, Sand PK, et al.  Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study.  J Urol.  2009;181(4): 1764-1772.
  2. Starkman JS, Dmochowski RR.  Management of overactive bladder with transdermal oxybutynin.  Rev Urol.  2006;8(3):93-103.
  3. Gelnique® (oxybutynin chloride) Gel 10% [prescribing information]. Corona, CA: Watson Pharmaceuticals, Inc.; 2008.
  4. Waldeck K, Larsson B, Andersson KE.  Comparison of oxybutynin and its active metabolite, N-desethl-oxybutynin, in the human detrusor and parotid gland.  J Urol.  1997;157(3):1093-1097.
  5. MacDiarmid S, Sandage BW Jr, Malhotra BK.  The effects of reformulation: improved therapeutic index.  Curr Urol Rep.  2008;9(6):465-471.

Website Graphics by Vintage Marketing